Further researches on roles of PTPN11, GRB2, SYK, PTPN6, SHC1 and immune cells infiltration in CAVD are needed whether it might be a new molecular targeted therapy for patients with CAVD. This evidence concerns the gene SHC1 and congenital bilateral aplasia of vas deferens from CFTR mutation.